Agnico Eagle Mines Limited (AEM)vsGlaxoSmithKline PLC ADR (GSK)
AEM
Agnico Eagle Mines Limited
$193.21
+2.90%
BASIC MATERIALS · Cap: $93.89B
GSK
GlaxoSmithKline PLC ADR
$50.41
-0.18%
HEALTHCARE · Cap: $101.38B
Smart Verdict
WallStSmart Research — data-driven comparison
GlaxoSmithKline PLC ADR generates 142% more annual revenue ($32.78B vs $13.54B). AEM leads profitability with a 39.5% profit margin vs 17.8%. GSK appears more attractively valued with a PEG of 0.50. AEM earns a higher WallStSmart Score of 75/100 (B+).
AEM
Strong Buy75
out of 100
Grade: B+
GSK
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-12.6%
Fair Value
$192.97
Current Price
$193.21
$0.24 premium
Margin of Safety
-3.1%
Fair Value
$56.71
Current Price
$50.41
$6.30 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 40 of every $100 in revenue as profit
Strong operational efficiency at 62.8%
Revenue surging 66.1% year-over-year
Earnings expanding 108.6% YoY
Conservative balance sheet, low leverage
Large-cap with strong market position
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 36.3%
Large-cap with strong market position
Attractively priced relative to earnings
Areas to Watch
Expensive relative to growth rate
1.5% revenue growth
Elevated debt levels
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AEM
The strongest argument for AEM centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 39.5% and operating margin at 62.8%. Revenue growth of 66.1% demonstrates continued momentum.
Bull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 36.3%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bear Case : AEM
The primary concerns for AEM are PEG Ratio.
Bear Case : GSK
The primary concerns for GSK are Revenue Growth, Debt/Equity, Altman Z-Score.
Key Dynamics to Monitor
AEM profiles as a growth stock while GSK is a value play — different risk/reward profiles.
AEM carries more volatility with a beta of 0.57 — expect wider price swings.
AEM is growing revenue faster at 66.1% — sustainability is the question.
AEM generates stronger free cash flow (727M), providing more financial flexibility.
Bottom Line
AEM scores higher overall (75/100 vs 66/100), backed by strong 39.5% margins and 66.1% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Agnico Eagle Mines Limited
BASIC MATERIALS · GOLD · USA
Agnico Eagle Mines Limited is engaged in the exploration, development and production of mineral properties in Canada, Sweden and Finland. The company is headquartered in Toronto, Canada.
Visit Website →GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Compare with Other GOLD Stocks
Want to dig deeper into these stocks?